02nd week of 2009 patent applcation highlights part 49 |
Patent application number | Title | Published |
20090012111 | Crystalline polymorph of 7-ethyl-10-hydroxycamptothecin - A crystalline polymorph of 7-ethyl-10-hydroxycamptothecin exhibiting an X-ray diffraction pattern having peaks at 10.9±0.2, 13.2±0.2, 23.9±0.2, and 26.1±0.2 2-theta degree. | 2009-01-08 |
20090012112 | Alpha 1A-adrenoceptor antagonists - This invention relates to novel compounds that are dihydroindoles derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel dihydroindoles derivatives that are derivatives of silodosin. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an α- | 2009-01-08 |
20090012113 | METHODS OF TREATING A SUBJECT SUFFERING FROM IRRITABLE BOWEL SYNDROME - Disclosed are methods of treating a subject suffering from irritable bowel syndrome which involves administering rifaximin to the subject and reducing the symptoms of irritable bowel syndrome. Also disclosed are methods of improving the symptoms in a subject caused by irritable bowel syndrome. | 2009-01-08 |
20090012114 | Cyclohepta[B]Pyridine-3-Carbonylguanidine Derivative and Pharmaceutical Product Containing Same - The present invention relates to a medicine, particularly a medicine comprising a novel cyclohepta[b]pyridine-3-carbonylguanidine derivative having an inhibitory effect on an Na | 2009-01-08 |
20090012115 | USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS - The present invention provides methods and compositions useful in the treatment or prevention of cardiovascular disorders in individuals for whom therapy with a COX-1 enzyme inhibitor is not feasible due to sensitivity, intolerance, or resistance to the inhibitor. Additionally, the invention provides methods of treating cardiovascular disorders in an individual who is receiving a therapeutically effective dose of a TP modulator and is instructed or advised to avoid and/or not to take aspirin or another COX-1 inhibitor. | 2009-01-08 |
20090012116 | Muscarinic Receptor Antagonists - Provided are muscarinic receptor antagonists, which can be useful in treating various diseases of the respiratory, urinary or gastrointestinal system mediated through muscarinic receptors. Also provided are processes for preparing compounds described herein, pharmaceutical compositions comprising compounds described herein, and methods for treating diseases mediated through muscarinic receptors. | 2009-01-08 |
20090012117 | Bicyclic derivatives as modulators of ion channels - Bicyclic derivatives having formula (I) and a composition thereof are useful as ion channel antagonists: | 2009-01-08 |
20090012118 | Kynurenic Acid Amide Derivatives as Nr2b Receptor Antagoni - The new kynurenic acid amide derivatives of formula (I): and optical antipodes, racemates and the salts thereof are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor. | 2009-01-08 |
20090012119 | FLUOROALKYLPYRROLIDINE DERIVATIVE - This invention relates to a compound represented by the following formula (1): | 2009-01-08 |
20090012120 | Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines - An ylide-based aza-Payne rearrangement of 2,3-aziridin- | 2009-01-08 |
20090012121 | POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE - The present invention provides novel crystal forms of fexofenadine hydrochloride Forms V, VI and VIII through XV and processes for their preparation and preparation of amorphous form and other crystalline forms of fexofenadine hydrochloride. Forms XIV and XV are solvates of ethyl acetate, while Form IX is a solvate of MTBE or cyclohexane. The forms are useful for administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compositions of the new crystalline forms. | 2009-01-08 |
20090012122 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS - Disclosed are N-aroyl cyclic amine derivatives having the formula: | 2009-01-08 |
20090012123 | Protective Agent for Retinal Neuronal Cell Comprising Indazole Derivative as Active Ingredient - As a result of intensive studies for the purpose of finding a new medicinal use of an indazole derivative, it was found that an indazole derivative inhibits glutamate-induced retinal neuronal cell death in rat fetal retinal neuronal cells, in other words, the indazole derivative acts directly on the retinal neuronal cells and exhibits an effect of protecting retinal neuronal cells. Accordingly, the indazole derivative is useful for the prevention or treatment of an eye disease associated with retinal neuronal cell damage or retinal damage. | 2009-01-08 |
20090012124 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors - The invention provides an acid addition salt of 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide and crystals thereof, the salt being formed with an acid selected from methanesulphonic acid and acetic acid and mixtures thereof. Also provided are the novel uses of salts of 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide, processes for the preparation of 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide and its salts and novel chemical intermediates. | 2009-01-08 |
20090012125 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them - The present invention provides a compound of a formula (I): [Chemical formula should be inserted here. Please see paper copy] wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state. | 2009-01-08 |
20090012126 | Certain chemical entities, compositions, and methods - Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described. | 2009-01-08 |
20090012127 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators - Compounds of Formula (I) wherein E, A and R1 are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same. | 2009-01-08 |
20090012128 | MICROBICIDAL AGENT AND MICROBICIDAL COMPOSITION - A microbicidal agent comprising as an effective ingredient at least one selected from the group consisting of p-hydroxybenzaldehyde, 5,7,4′-trihydroxy-3′,5′-dimethoxyflavone, 3-hydroxypyridine and vanillin, and a microbicidal composition comprising the microbicidal agent. | 2009-01-08 |
20090012129 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS - Novel biaromatic compounds that modulate peroxisome proliferator-activator receptors, known as PPAR, having the formula (I): | 2009-01-08 |
20090012130 | Strategies for Designing Drugs that Target the Sir2 Family of Enzymes - The instant invention describes methods of identifying compounds that modulate the activity of Sir2 enzymes. Sir2 enzymes form a unique class Of NAD | 2009-01-08 |
20090012131 | 4-OXY-N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE - The present invention comprises 4-Oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, the derivatives thereof and salts thereof as well as processes for their preparation and methods for their use as pharmaceutical compositions. More specifically, the invention relates to 4-oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives that exhibit peroxisome proliferator activator receptor (PPAR) PPARalpha, PPARdelta and PPARgamma agonist activity. The compounds themselves are defined by the structure of the formula I, | 2009-01-08 |
20090012132 | Pharmaceutical Package - The present invention relates to a pharmaceutical package including a pharmaceutical preparation containing 2-ethoxy-1-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl or 2-cyclopropyl-1-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl or a salt thereof, and a desiccant. According to the present invention, a pharmaceutical package having a decreased uncomfortable odor is provided. | 2009-01-08 |
20090012133 | Polymorphic Form of -Acetic Acid - The present invention relates to a novel polymorphic form of the compound {2-methyl-4-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethylthio]phenoxy}-acetic acid, methods of preparing it, pharmaceutical compositions and medicaments containing the same, and use of such polymorphs, compositions and medicaments in the treatment of PPAR mediated diseases or conditions. | 2009-01-08 |
20090012134 | Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists - Compounds of formula (I): are potent and selective antagonists of the 5-HT | 2009-01-08 |
20090012135 | ISOTHIAZOLONE-CONTAINING PRESERVATIVE WITH IMPROVED EFFECTIVENESS - The invention relates to a preservative which 5 comprises a) one or more isothiazolones and b) one or more glycerol monoalkyl ethers, to the use of the preservatives for microbicidal finishing of cosmetic and pharmaceutical products, and to corresponding microbicidally finished products. | 2009-01-08 |
20090012136 | UNIT DOSE FORMULATIONS AND METHODS OF TREATING AND PREVENTING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS - The present invention provides new methods of treating thrombosis and cardiovascular diseases using of antithrombotic agents, as well as methods of determining therapeutically effective amounts of antithrombotic agents and unit dose formulations thereof. | 2009-01-08 |
20090012137 | ANTMICROBIAL AND RADIOPROTECTIVE COMPOUNDS - The present invention relates to a method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering an effective amount of a compound of formula (I), in which X and Y are either the same or different and selected from a heteroatom; is a double or single bond depending on the heteroatoms X and Y; R | 2009-01-08 |
20090012138 | 4-IMIDAZOLINES - The present invention relates to compounds of formula | 2009-01-08 |
20090012139 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE - The present invention provides a 2-amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compound of formula I | 2009-01-08 |
20090012140 | Preparation of Telmisartan Salts with Improved Solubility - New alkali and earth-alkali salts of telmisartan in amorphous form and a new crystalline sodium salt of telmisartan have been prepared by preparing a solution despite low solubility of telmisartan and rapidly vacuum evaporating to dryness. | 2009-01-08 |
20090012141 | Composition and Method for Making Oligo-Benzamide Compounds - The present invention includes compound compositions and methods of making compounds that include an oligo-benzamide compound having at least two optionally substituted benzamides. | 2009-01-08 |
20090012142 | Compositions and Methods for Increasing Lean Muscle Mass and/or Reducing Fat Gain - Compositions and methods for increasing lean muscle mass and/or reducing fat gain in growing animals by feeding the animals a composition having a total lysine to metabolizable energy ratio of from about 2.5 to about 6 g/Mcal and comprising (a) arginine in a total arginine to total lysine ratio of from about 1.1 to about 1.6; (b) isoleucine in a total isoleucine to total lysine ratio of from about 0.8 to about 1.3; (c) leucine in a total leucine to total lysine ratio of from about 1.8 to about 3.0; (d) valine in a total valine to total lysine ratio of from about 0.8 to about 1.4; and (e) methionine and cystine in a total methionine plus cystine to total lysine ratio of from about 0.8 to about 1.7. | 2009-01-08 |
20090012143 | CHEMICAL COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF - Disclosed are compounds of formula (I) or pesticidally acceptable salts thereof wherein, for example, W is ═CR | 2009-01-08 |
20090012144 | Optically active 2,5-bisaryl-delta¹ -pyrrolines and their use as pest control agents - Novel optically active Δ | 2009-01-08 |
20090012145 | THERAPEUTIC ESTERS - A compound comprising | 2009-01-08 |
20090012146 | SOLUBILITY-ENHANCED PHARMACEUTICAL COMPOSITIONS COMPRISING ZAFIRLUKAST - Stable pharmaceutical compositions comprising zafirlukast and pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or mixtures thereof, together with one or more pharmaceutically acceptable polymers, and processes for their preparation. | 2009-01-08 |
20090012147 | Indolone Derivatives, Processes For Preparing Them And Their Uses - The present invention relates to indolone derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2009-01-08 |
20090012148 | REDUCING CELLULAR CHOLESTEROL LEVELS AND/OR TREATING OR PREVENTING PHOSPHOLIPIDOSIS - Compounds disclosed herein may be used in disclosed methods for reducing the amount of cholesterol in a cell, for treating a patient suffering from a disorder characterized by cellular accumulation of cholesterol (such as Niemann-Pick Disease Type C or atherosclerosis), and/or for treating or preventing phospholipidosis. In some embodiments, the compounds may include a pyrrolone or triazine moiety. | 2009-01-08 |
20090012149 | PRODRUG OF AN ICE INHIBITOR - This invention describes an ICE inhibitor prodrug (I) having good bioavailability. | 2009-01-08 |
20090012150 | Stablized Pharmaceutical Composition Comprising an Amorphous Active Substance - The invention relates to the pharmaceutical composition comprising the amorphous active substance which is atorvastatin calcium. The process of stabilization of the pharmaceutical composition comprising the pharmaceutical formulation with amorphous atorvastatin calcium, the process of stabilization of the pharmaceutical formulation comprising amorphous atorvastatin calcium and the process of stabilization of atorvastatin calcium in an amorphous form is described. | 2009-01-08 |
20090012151 | Novel Compounds 951 - The present invention relates to amide compounds useful as pharmaceuticals for treating respiratory disorders such as asthma, rhinitis and COPD. | 2009-01-08 |
20090012152 | Use of Tetramic Acid Derivatives for Controlling Insects from the Genus of the Plane Lice (Sternorrhyncha) - The present invention relates to the use of tetramic acid derivatives of the formula (I) | 2009-01-08 |
20090012153 | AMINOACID DERIVATIVES CONTAINING A DISULFANYL GROUP IN THE FORM OF MIXED DISULFANYL AND AMINOPEPTIDASE N INHIBITORS - The invention relates to novel compounds of formula (I): H | 2009-01-08 |
20090012154 | Antagonists of the transient receptor potential vanilloid 1 and uses thereof - One of the major disabling symptoms of gastroparesis is nausea and vomiting which can be difficult to control with currently available treatments. It is postulated that signaling of gastrointestinal causes of nausea starts with activation of vagal afferent nerves that trigger the central emetic pathway. Most vagal afferent nerves are unmyelinated C-fibers, many of which express the vanilloid receptor TRPV1 and respond to capsaicin. Resiniferatoxin is a very potent capsaicin analogue that has a much more favorable ratio of desensitization to excitation than capsaicin leading to more effective desensitization without irritation. The present invention demonstrates that desensitization of TRPV1 responsive gastric sensory neurons would attenuate nausea and vomiting. | 2009-01-08 |
20090012155 | Composition Of Skin External Application For Anti-Aging - The present invention relates to an anti-aging composition for external use on skin, and more particularly, to an anti-aging composition for external use on skin comprising at least one of catechins and flavonols as an active ingredient to inhibit decomposition and promote generation or protection at the dermis-epidermis junction. | 2009-01-08 |
20090012156 | Composition comprising polyphenol - A fat based spread or a dairy based drink comprising from to 1 wt % of isorhamnetin can advantageously be used to control blood pressure. It has been found that these products have an effect on vasorelaxation. | 2009-01-08 |
20090012157 | Sesamol Derivatives as Novel Inhibitors of Arachidonic Acid Formation - The invention relates to a novel class of inhibitor of arachidonic acid useful for treating inflammatory conditions. Specifically, the invention relates to hydrophobic and hydrophilic derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol. | 2009-01-08 |
20090012158 | Pesticide Compositions and Methods - New pesticide compositions comprising an alkyl formate and an isothiocyanic ester are described, as are methods of delivering fumigants and methods of pest control using a combination of fumigants. | 2009-01-08 |
20090012159 | HIGH PURITY BASES OF 3,3-DIPHENYLPROPYLAMINO MONOESTERS - The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C | 2009-01-08 |
20090012160 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof - The present invention discloses novel dual prodrug compounds of formula (1), methods for their preparation and intermediates in their syntheses, formula (1): wherein A is a single bond, —O—, or —CH | 2009-01-08 |
20090012161 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor - This invention describes a new combination for the treatment of bladder function disorders which comprises a serotonin- and/or norepinephrine-reuptake inhibitor and a beta-3-adrenoceptor agonist. | 2009-01-08 |
20090012162 | Composition for treating or preventing cell degeneration using at least one molecule capable of maintaining adhesion molecule expression reversibility and vascular endothelium actin fibre polymerisation - The invention relates to the use of a molecule selected from the group which consists of geranyl acetate, geraniol, isomenthone, limonene or a mixture of at least two of the above, for preparing a drug for treating or preventing vascular endothelial cell senescence and subjacent tissue degeneration induced by repeated inflammatory episodes. Specifically, the drug is useful for treating vascular endothelial cell senescence and tissue degeneration induced by repeated inflammatory episodes resulting from the presence of cancer cells. | 2009-01-08 |
20090012163 | Compositions containing Mg/Zn/F-CaP plus inhibitors of pro-inflammatory cytokines (alpha ketoalkanoic acid compound) for osteoporosis prevention, therapy and treatment of bone diseases - A method is described for the treatment of bone disease by oral dosing of a patient with an inhibitor(s) or pro-inflammatory Cytokines which are comprised of a combination of alpha ketoalkanoic acid admixed in a pharmaceutically acceptable carrier with calcium/phosphate/magnesium/zinc or strontium salt compound ion—a hydroxyapatite matrix. | 2009-01-08 |
20090012164 | PINOLENIC ACID COMPOSITIONS, PRODUCTS MADE THEREOF, AND METHODS OF MAKING PINOLENIC ACID COMPOSITIONS AND PRODUCTS - Compositions of pinolenic acid or derivatives thereof. Method of using TOFA for obtaining pinolenic acid or derivatives thereof. Products, including foods, beverages, personal care, beauty, pharaceutical or other products comprising TOFA derived pinolenic acid or derivatives thereof. | 2009-01-08 |
20090012165 | PHARMACEUTICAL COMBINATION OF NSAID AND PROSTAGLANDIN COMPOUND - Provided is a method for treating a condition or disease which is one of the indications for NSAID use, which comprises administering a combination of:
| 2009-01-08 |
20090012166 | Oligomers of Straight-Chain and Unbranched Fatty Acids and Drugs Containing These - The present invention relates to new substances which are derived from naturally occurring straight-chain and unbranched fatty acids and also from semi-synthetic and synthetic compounds with principally the same structure in that they represent dimers, trimers, tetramers or higher oligomers of the starting substances. | 2009-01-08 |
20090012167 | Omega-3 Fatty Acids and Dyslipidemic Agent for Lipid Therapy - A method and composition for blood lipid therapy by administering to the subject an effective amount of a dyslipidemic agent and omega-3 fatty acids. The method utilizes a single administration or a unit dosage of a combination of dyslipidemic agent and omega-3 fatty acids for the treatment of patients with hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease (CHD), vascular disease, artherosclerotic disease and related conditions, and the prevention or reduction of cardiovascular and vascular events. | 2009-01-08 |
20090012168 | ADIPONECTION INDUCERS OR SECRETAGOGUES - The present invention discloses an adiponectin inducer or secretagogue which comprises an amino acid(s) selected from the group consisting of leucine, isoleucine, valine, methionine, cystein, alanine and a mixture(s) thereof, and a therapeutic agent of hypoadiponectinemia, hyperlipemia, hypertension or vascular disorders or an anti-inflammatory agent, which comprises the adiponectin inducer or secretagogue. | 2009-01-08 |
20090012170 | TREATMENT OF SYMPTOMS OF MOTOR DYSFUNCTION - The present invention relates to the use of a COMT inhibitor in combination with a dopamine precursor and a peripheral decarboxylase inhibitor in the treatment of motor dysfunctions. | 2009-01-08 |
20090012171 | Novel Compounds, Their Preparation and Use - Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype. | 2009-01-08 |
20090012172 | Cosmetic/pharmaceutical compositions comprising retinoids and anti-irritants and treatment of keratinization disorders therewith - Topically applicable cosmetic/pharmaceutical compositions contain at least one retinoid and at least one anti-irritant compound selected from among the salts of 18β-glycyrrhetinic acid and derivatives thereof, and are useful for the treatment and/or prevention of a dermatological condition or affliction related to a disorder of keratinization relating to cell differentiation and to cell proliferation, e.g. acne vulgaris. | 2009-01-08 |
20090012173 | Method for treatment of nocturia - A method for treatment of nocturia by administering to a mammal, such as a human, in need of such treatment, a therapeutically effective amount of loxoprofen or a pharmacologically acceptable salt thereof. | 2009-01-08 |
20090012174 | Compositions Having a High Antiviral and Antibacterial Efficacy - Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain (a) a disinfecting alcohol, (b) an organic acid, (c) a buffering agent, and (d) water, wherein the composition has a pH of about 5 or less. | 2009-01-08 |
20090012175 | Methods of treating cancer with HDAC inhibitors - The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. | 2009-01-08 |
20090012176 | PROCESS FOR MANUFACTURING ENTACAPONE - Processes for manufacturing entacapone are provided. | 2009-01-08 |
20090012177 | Treatment of psychiatric disorders using entacapone, tolcapone and other COMT inhibitor or MB-COMT inhibitor drugs - The invention provides a method for the treatment of certain psychiatric disorders using entacapone, tolcapone and other COMT inhibitor drugs or MB-COMT inhibitor compounds. The method is effective in particular for improving positive and negative symptoms of Schizophrenia (SCZ), major depression, the depressive phase of Bipolar Disorder (BD) and substance dependency. The method can also be used as a treatment to combat cravings associated with abuse of alcohol, opiates, cocaine, marijuana, amphetamines and Tobacco addiction. In addition to these diseases it is useful for the treatment of ADD/ADHD, cognitive enhancement in head injuries and dementias. | 2009-01-08 |
20090012178 | Benzoxazocines and Their Therapeutic Use - A compound selected from (1S)-8-cyano-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5H-benz[f]-2,5-oxazocine; (1R)-8-cyano-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5H-benz[f]-2,5-oxazocine; (1S)-8-cyclopropyl-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5H-benz[f]-2,5-oxazocine; (1S)-8-cyclopropyl-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5H-benz[f]-2,5-oxazocine; (1S)-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5H-benz[f]-2,5-oxazocine-8-carboxamide; (1R)-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5H-benz[f]-2,5-oxazocine-8-carboxamide; and the salts thereof. These compounds have therapeutic utility. | 2009-01-08 |
20090012179 | Use of Tyrphostins to Stimulate Neurite Outgrowth - Disclosed herein are several methods for promoting nerve regeneration. The methods include administering at least one tyrphostin, or a pharmaceutically acceptable salt thereof. In one non-limiting example, the tyrphostin is tyrphostin A9. These methods can be used to promote nerve growth in the central or peripheral nervous system. The methods are of use in treating neurodegenerative diseases, such as Parkinson's disease, or in treating the transaction of a partial or complete transaction of a nerve in the peripheral or central nervous system. | 2009-01-08 |
20090012180 | Titration of Tapentadol - The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a2009-01-08 | |
20090012181 | Patch - A Bisoprolol patch, wherein the skin penetration rate of Bisoprolol after 24 hours is 15 to 60% of the maximum skin penetration rate thereof, shows a little difference between the maximum level of the concentration in blood and the minimum level thereof in repeated administration and, therefore, scarcely exhibits side effects. Moreover, it achieves the quick development of the drug effect owing to the stabilization of the concentration in blood within a short time. | 2009-01-08 |
20090012182 | Crystal forms of O-desmethylvenlafaxine succinate - Provided are crystalline forms of O-desmethylvenlafaxine succinate, methods for their preparation, and pharmaceutical composition thereof. | 2009-01-08 |
20090012183 | Composition comprising polyphenol - A food product comprising from 0.05 to 1 wt % of trans-resveratrol can advantageously be used to control blood pressure. Preferred food products are spreads or drinks. | 2009-01-08 |
20090012184 | Production of Dosage Forms Comprising a Solid Dispersion of a Microcrystalline Agent - A method is described for the production of dosage forms, which comprise a solid dispersion of a microcrystalline active substance, in which a thermoplastic polymer with a glass transition temperature Tg of at least 40° C. is melted and an active substance is dissolved homogeneously in the melt; crystallization of the active substance is initiated in the mass obtained; and the mass is cooled. Crystallization of the active substance can be initiated by adding a nonsolvent, seed crystals of the active substance or a derivatization reagent. In addition, crystallization can be initiated by holding the mass for a sufficient length of time at a temperature that is below the temperature at which the active substance is completely soluble in the mass. | 2009-01-08 |
20090012185 | Surfactant Composition - A surfactant composition contains at least one sorbitan ester and at least one sorbitol ester wherein the mean number of carbon atoms of the hydrophobe of the sorbitan ester is greater than that of the sorbitol ester. The surfactant composition is particularly suitable for use in stabilising emulsions, especially personal care or cosmetic products. | 2009-01-08 |
20090012186 | Mite Composition, Use Thereof, Method for Rearing the Phytoseiid Predatory Mite Amblyseius Sirskii, Rearing System for Rearing Said Phytoseiid Mite and Methods for Biological Pest Control on a Crop - The present invention relates to a novel mite composition comprising a population of the phytoseiid predatory mite species | 2009-01-08 |
20090012187 | Emulsions and Techniques for Formation - The present invention generally relates to emulsions such as multiple emulsions, and to methods and apparatuses for making emulsions, and techniques for using the same. A multiple emulsion generally describes larger droplets that contain one or more smaller droplets therein which, in some cases, can contain even smaller droplets therein, etc. Emulsions, including multiple emulsions can be formed in certain embodiments with generally precise repeatability, and can be tailored to include any number of inner droplets, in any desired nesting arrangement, within a single outer droplet. In addition, in some aspects of the invention, one or more droplets may be controllably released from a surrounding droplet. | 2009-01-08 |
20090012188 | Process for the production of synthesis gas with conversion of CO2 into hydrogen - Process for the production of liquid hydrocarbons from a feedstock that comprises at least one elementary feedstock from the group of biomass, coal, lignite, petroleum residues, methane, and natural gas, comprising: at least one stage a) for gasification of the feedstock by partial oxidation and/or steam reforming to produce a synthesis gas SG; a stage b) for separating CO2 from SG and a portion of the effluent of the subsequent stage c); the mixing of a portion of the CO2 that is separated with a gas of an H2/CO ratio of more than 3; a stage c) for partial conversion with hydrogen, thermal or thermocatalytic, of the CO2 that is present in said first mixture according to the reaction: CO2+H2→CO+H2O in a specific reaction zone that is separated from said gasification zone or zones; a stage d) for Fisher-Tropsch synthesis on a synthesis gas that comprises at least a portion of SG and at least a portion of the CO that is produced by the conversion of CO2 into hydrogen. | 2009-01-08 |
20090012189 | Catalyst Bodies for Use in Fischer-Tropsch Reactions - The invention relates to a catalyst body comprising a Fischer-Tropsch catalyst or catalyst precursor and a porous body, said porous body being between 1-50 mm, preferably 1-30 mm in size, the catalyst body having an internal voidage between 50-95%. The invention further relates to a process comprising the steps of: (i) introducing the synthesis gas into the reactor; and (ii) contacting the synthesis gas with a non-stationary catalyst to catalytically convert the synthesis gas at an elevated temperature to obtain the normally gaseous, normally liquid, and optionally normally solid hydrocarbons from synthesis gas; wherein the catalyst of step (ii) is located on a plurality of porous bodies being 1-50 mm in size, preferably 1-30 mm in size, thus forming catalyst bodies, and wherein said catalyst bodies have an external voidage in situ in the reactor between 5-60%, and a porosity within the catalyst bodies between 50-95%. Use of catalyst bodies according to the invention provides an advantageous intermediate balance whereby such catalyst bodies are significantly easier (and therefore less costly) to separate from the products of the slurry reactor, but they are still able to be supported by the slurry, and are therefore still movable within the reactor vessel so as to seek the most even catalytic transfer and heat transfer, but without being fixed. | 2009-01-08 |
20090012190 | Polymeric Media Comprising Polybenzimidazoles N-substituted with Organic-Inorganic Hybrid Moiety - A PBI compound includes imidazole nitrogens at least a portion of which are substituted with an organic-inorganic hybrid moiety. At least 85% of the imidazole nitrogens may be substituted. The organic-inorganic hybrid moiety may be an organosilane moiety, for example, (R)Me | 2009-01-08 |
20090012191 | LIGHTWEIGHT WALL STRUCTURE MATERIAL AND PROCESS FOR MAKING - This invention relates to a method for creating a lightweight cementatious material for use in building construction. The material can be formed in panels to replace conventional drywall gypsum board. In the disclosed form the product does not include any paper or other components that serve as food for mold and therefore is mold resistant. The material has a composition of Portland cement, foamed glass beads and an acrylic co-polymer. In some forms, sand may be used as a filler and in others, the filler may be polystyrofoam particles and vermiculite. | 2009-01-08 |
20090012192 | Low Scorching Flame Retardants for Colored Polyurethane Foams - Flame retarded, colored polyurethane foam compositions having reduced discoloration, said foam compositions comprising a foam, which is the reaction product of a polyol and an isocyanate, a colorant, a flame retardant of the type that normally causes scorch and a benzofuranone derivative, as an anti-scorch stabilizer. | 2009-01-08 |
20090012193 | Multifunctional Ethynyl Substituted Monomers and Polyarylene Compositions Therefrom - A compound (monomer) comprising i) one or more arylethynyl groups (A-functional groups), ii) one or more ring structures comprising two conjugated carbon-to-carbon double bonds and a leaving group L (B-functional groups), and iii) one or more ethynyl groups (C′-functional groups), characterized in that said A- and C′-functional groups are capable of reaction under cycloaddition reaction conditions with said B-functional groups to thereby form a cross-linked, polyphenylene polymer. | 2009-01-08 |
20090012194 | Foam - The present invention provides a foam comprising (a) a polylactic acid resin, (b) at least one thermoplastic resin selected from a polyolefin resin and a polystyrene resin, and (c) a block copolymer of a vinyl aromatic compound and a conjugated diene, wherein a ratio of (a) to (b) by weight (a/b) is 80/20 to 20/80, and the foam comprises 0.5 to 20 parts by weight of (c) with respect to 100 parts by weight of (a) and (b) in total. | 2009-01-08 |
20090012195 | RESIN COMPOSITION FOR USE IN FORMING A POLYURETHANE ARTICLE WITH INCREASED COMFORT - A unique combination of a hydrophilic polyol (A) and a hydrophobic polyol (B) having a terminal ethylene oxide cap are used in a resin composition and a polyurethane system, and are used to form a polyurethane article, such as a polyurethane foam. The hydrophilic polyol (A) is ethylene oxide (EO) rich and the hydrophobic polyol (B) is propylene oxide (PO) rich. The hydrophilic polyol (A) and the hydrophobic polyol (B) are present in the resin composition and the polyurethane system in a weight ratio (A:B) of from 1.5:1 to 20:1. The polyurethane article exhibits excellent comfort for use in vehicle applications, such as automotive and motorcycle seating, due to reduced resonance frequency and reduced peak vibration transmissivity relative to previous polyurethane articles. | 2009-01-08 |
20090012196 | CONDUCTIVE TONER SUPPLY ROLLER, METHOD OF MANUFACTURING SUPPLY ROLLER, AND ELECTROSTATIC RECORDING APPARATUS HAVING THE SUPPLY ROLLER - A conductive toner supply roller and a method of manufacturing the supply roller. The method includes preparing a polyurethane foam, impregnating the polyurethane foam with an impregnation solution including an electroconductive polymer, a binder resin, an electroconductive agent and a solvent, and drying the resulting polyurethane foam, cutting the dried polyurethane foam, and inserting a shaft into the cut polyurethane foam, and polishing an outer surface of the resulting polyurethane foam. The resulting conductive toner supply roller has a low or medium resistance, and may be user in an electrostatic recording apparatus such as a printer, a facsimile machine, a copier or the like. | 2009-01-08 |
20090012197 | USE OF LOW-VISCOSITY AQUEOUS HOT-CURE FLEXIBLE POLYURETHANE FOAM STABILIZER SOLUTIONS CONTAINING POLYETHERSILOXANES IN THE PRODUCTION OF HOT-CURE FLEXIBLE POLYURETHANE FOAMS - The subject matter of the present invention relates to a low-viscosity aqueous hot-cure flexible polyurethane foam stabilizer solution which can be used in the production of hot-cure flexible polyurethane foams, wherein the low-viscosity aqueous hot-cure flexible polyurethane foam stabilizer solution comprises the following components: ≧40% to ≦70% by weight of polyethersiloxane, ≧0.5% to ≦20% by weight of organic surfactant, ≧10% by weight of water, ≧0% by weight of organic solvent additions, in which the polyethersiloxane has the following formula (I) —R | 2009-01-08 |
20090012198 | Ultraviolet Ray Curing Type Resin Composition - An ultraviolet ray curing type resin composition comprising (A) an urethane acrylate produced from, as essential ingredients, an isocyanate compound comprising an aliphatic isocyanate compound and an alicyclic isocyanate compound at a molar ratio of from 80/20 to 20/80; a polyol compound comprising an ester-based polyol, an ether-based polyol or a polycarbonate-based polyol; and an acrylate compound having a hydroxyl group, (B) an acrylate-based reactive diluent, and (C) a photo-reactive initiator. The coated film obtained by coating the composition to a substrate, followed by photocuring has a following capability in molding owing to its excellent elongation, and only-causes a low level of yellowing upon long time heating to show an excellent thermal resistance. The cured product has a decreased residual odor and, therefore, useful in improving designing property and beauty in using for an automobile interior or the like. Further, the composition is suitable for forming a matted surface by printing to a substrate. | 2009-01-08 |
20090012199 | Photoinitiator anchored to silicate and use thereof to prepare polymer exfolidated silicate nanocomposite - Photoinitiator modified silicate and ethylenically unsaturated monomer are reacted in solvent to cause living polymerization of monomer and exfoliation of silicate layers and cause attachment of silicate layers to polymer chains, thereby providing dispersed homopolymer or block copolymer silicate nanocomposites. | 2009-01-08 |
20090012200 | PROCESS FOR DEMETALLIZATION OF CARBON NANOTUBES - Processes are provided for removing metal-based catalyst residues from carbon nanotubes by contacting the carbon nanotubes with an active metal agent and carbon monoxide. | 2009-01-08 |
20090012201 | UV-Curable Aqueous Emulsion, Preparation Thereof And Solventless Coating Composition Comprising The Same - The UV-curable aqueous coating composition is characterized by using a UV-curable aqueous emulsion obtained by urethane reaction with a mixture including a poly-carbonate polyol or polyester polyol; an isocyanate compound; a urethane-reactive carboxylic acid; a UV-curable acrylic oligomer having 2 to 9 functional acrylate groups; a UV-curable acrylic monomer; and a urethane-reactive acrylate without an organic solvent. The aqueous composition provides good environmental acceptability and satisfactory film properties comparable to those of the prior oily UV-curable coating composition and, therefore, it is useful for coating various plastics. | 2009-01-08 |
20090012202 | Acrylated Urethanes, Processes for Making the Same and Curable Compositions Including the Same - The present invention is directed to acrylated urethanes including the reaction product of: (1)(a) at least one urethane having at least two isocyanate groups and at least one acrylate group; and (b) at least one alcohol compound having at least two hydroxyl groups; or (2) (a) at least one isocyanate functional urethane which is the reaction product of at least one alcohol compound selected from the group consisting of amino alcohols, thioether alcohols, phosphino alcohols and mixtures thereof and at least one polyisocyanate; and (b) at least one hydroxy-functional material having at least one acrylate group; curable compositions including the same and processes for making the same. | 2009-01-08 |
20090012203 | Epoxy Resin and Epoxy Resin Composition - [PROBLEMS] The present invention relates to a crystalline epoxy resin, which gives a cured object excellent in various properties including flame retardancy, low water absorption, and impact resistance. The object of the present invention is to provide epoxy resin which is useful as an optical material, an epoxy resin composition containing crystals of the epoxy resin having excellent storage stability and a cured object obtained from the composition.
| 2009-01-08 |
20090012204 | FUNCTIONALIZATION OF POLYMERS WITH REACTIVE SPECIES HAVING BOND-STABILIZED DECONTAMINATION ACTIVITY - Functionalized polymers and methods of functionalizing polymers with reactive species having decontaminating activity, such as polyoxometalates and metal oxides. Covalent bonding of the reactive species to the polymer securely immobilizes the reactive species and stabilizes the decontaminating activity of the reactive species. Specifically, the covalent bonding of the reactive species greatly reduces moisture deactivation during prolonged exposure to atmospheric moisture. Polyoxometalates are catalytically reactive through oxidative pathways and metal oxides are reactive through hydrolytic pathways. Both polyoxometalates and metal oxides having oxygen atoms available for covalent bonding with an appropriate bifunctional linking agent. | 2009-01-08 |
20090012205 | TRANSPARENT GEL AND CONTACT LENSE FROM THE SAME - A transparent gel is disclosed which has an interpenetrating polymer network of a copolymer containing a polysiloxane structure and a polycarbonate structure and a hydrophilic polymer obtained by polymerizing a hydrophilic monomer. The transparent gel is useful as a cultivation substrate, a container for storage and an ophthalmic material, comprising an easily synthesizable and purifiable silicon-containing resin, wherein a gel strength, transparency, oxygen permeability, birefringence and other characteristics are excellent. | 2009-01-08 |
20090012206 | MEDICAL ADHESIVES FOR SURGERY - The present invention relates to novel, rapidly curing adhesives based on hydrophilic polyisocyanate prepolymers for use in surgery. | 2009-01-08 |
20090012207 | USE OF COLOURED POLYMERIC SYSTEMS FOR MEDICAL OR HYGIENE ARTICLES - Use of colored polymer systems having a color which is changeable in the case of a strain for indicating the stress state of hygiene or medical articles adjacent to the body. | 2009-01-08 |
20090012208 | Medical Device Having a Wetted Hydrophilic Coating - The present invention relates to a medical device having a wetted hydrophilic coating comprising:
| 2009-01-08 |
20090012209 | DENTAL COMPOSITIONS CONTAINING A SURFACE-MODIFIED FILLER - The present invention features ionomer compositions containing a filler surface modified with a polyacid. The compositions can be used in a variety of dental and orthodontic applications, for example, as adhesives, cements, restoratives, coatings and sealants. | 2009-01-08 |
20090012210 | BIODEGRADABLE AND COMPOSTABLE COMPOSITION HAVING IMPROVED PHYSICAL AND CHEMICAL PROPERTIES - The present application is generally directed to novel compositions and methods used to produce a biodegradable, starch-based, water-resistant article of manufacture. The teachings include a composition comprising a biodegradable fiber component in an amount ranging from about 5% to about 40% on a dry weight basis, starch component in an amount ranging from about 40% to about 94.5% on a dry weight basis, and an additive component in an amount ranging from more than 0% to about 15% on a dry weight basis. The additive component can comprise an epoxidized vegetable oil, a hydrogenated triglyceride, poly(vinyl acetate), poly(vinyl acetate-ethylene) copolymer, poly(ethylene-vinyl acetate) copolymer, or a combination thereof. | 2009-01-08 |
20090012211 | Novel biodegradable nanocomposites - Biodegradable compositions of clay, diphosphates and biodegradable polymers are described. The diphosphates may be resorcinol diphosphate or bisphenol diphosphate. The biodegradable polymer may be a cellulose. | 2009-01-08 |